Combination Hyaluronic Acid and Multipotent Stromal Cells Fails to Improve Rat Knee OA Outcomes Compared to Cells Alone
- PMID: 40666263
- PMCID: PMC12262070
- DOI: 10.2147/ORR.S525292
Combination Hyaluronic Acid and Multipotent Stromal Cells Fails to Improve Rat Knee OA Outcomes Compared to Cells Alone
Abstract
Introduction: Multipotent Stromal Cells (MSCs) are utilized as therapeutic agents for addressing musculoskeletal conditions, including knee osteoarthritis (OA). However, major challenges in the clinical application include maintenance of the cells in the joint capsule. Hyaluronic acid (HA) is endogenous in synovial joints and commercially available as a joint lubricant. We tested the hypothesis that delivery of MSCs in HA into an OA rat knee model could improve outcomes.
Methods: Rat bone marrow MSCs were suspended in a commercially available HA paste, and cell viability measured with live/dead stains. Biomarkers for MSC chondrogenesis and osteogenesis were monitored with PCR. MSCs with or without HA were injected into the knees of OA rats and histology conducted 6 weeks later.
Results: Suspending MSC in HA resulted in a slight reduction in viability. The gene expression profile showed an increase in MSC biomarkers for cells in HA with a decrease in osteogenic markers. Four groups of treatment (vehicle, MSCs alone, HA alone, MSCs + HA) were injected into the knees of osteoarthritic rats. Pain scores, collected weekly, showed no difference between the groups. Immunohistochemistry for inflammatory markers illustrated no obvious differences between groups. Proteoglycans, indicative of cartilage, showed a loss in the vehicle group and modest signs of cartilage with MSCs alone, but when mixed with the HA, any benefit was lost. OARSI Histological Scoring completed by 2 independent technicians concluded no improvement in joint integrity with the addition of HA.
Conclusion: A commercially available HA failed to enhance joint regeneration compared to MSCs alone.
Keywords: Hyaluronic acid; multipotent stem cell; osteoarthritis.
© 2025 Davis et al.
Conflict of interest statement
MH, DM, AW, SH and LSB are employees of Likarda, Inc, which gains no benefit from the results of this study. LSB is also the founder and has equity in Likarda, Inc. The authors report no other conflicts of interest in this work.
Figures





Similar articles
-
Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle.Cochrane Database Syst Rev. 2015 Oct 17;2015(10):CD010643. doi: 10.1002/14651858.CD010643.pub2. Cochrane Database Syst Rev. 2015. PMID: 26475434 Free PMC article.
-
Human Infrapatellar Fat Pad Mesenchymal Stem Cell-derived Extracellular Vesicles Purified by Anion Exchange Chromatography Suppress Osteoarthritis Progression in a Mouse Model.Clin Orthop Relat Res. 2024 Jul 1;482(7):1246-1262. doi: 10.1097/CORR.0000000000003067. Epub 2024 Apr 19. Clin Orthop Relat Res. 2024. PMID: 38662932 Free PMC article.
-
Intraarticular corticosteroid for treatment of osteoarthritis of the knee.Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005328. doi: 10.1002/14651858.CD005328.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2015 Oct 22;(10):CD005328. doi: 10.1002/14651858.CD005328.pub3. PMID: 16625636 Updated.
-
Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal Cells, or Placebo in Knee Osteoarthritis: A Network Meta-analysis.Arthroscopy. 2021 Jan;37(1):292-306. doi: 10.1016/j.arthro.2020.03.041. Epub 2020 Apr 17. Arthroscopy. 2021. PMID: 32305424
-
Health Economic Assessments of Hyaluronic Acid Treatments for Knee Osteoarthritis: A Systematic Review.Adv Ther. 2024 Jan;41(1):65-81. doi: 10.1007/s12325-023-02691-y. Epub 2023 Oct 30. Adv Ther. 2024. PMID: 37899384
References
LinkOut - more resources
Full Text Sources